Anti-Mouse Thy1.1/CD90.1 Antibody (19E12)
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is an anti-mouse Thy1.1/CD90.1 IgG2a monoclonal antibody. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can deplete CD90.1+ cells. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can clear Tregs. Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) can be used for researches on inflammation conditions and immune response such as airway inflammation and experimental autoimmune encephalomyelitis (EAE).
For research use only. We do not sell to patients.
- Purity: 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mouse IgG2a kappa
Mouse
Thy1.1/CD90.1
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) (250 μg, i.p., single dose, 133 days after the injection of Tregs-IL2pa) can clear Tregs in male B6 Thy1.2 mice with a cell transplantation model[2].
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) (200 µg, i.p. once every other day, until symptoms of the disease appear) exhausts Thy1.1+ dendritic cells (DCs) in C57BL/6 mice with a MOG35-55 (HY-P1240) induced experimental autoimmune encephalomyelitis (EAE) model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:10BiT/Foxp3eGFP mice (6-8 weeks) with HDM (20 μg) induced allergic airway inflammation model[1]
-
Dosage:200 μg
-
Administration:Intraperitoneal injection (i.p.), single dose on day 8 for the acute model and once daily from day 64 or day 67 for the memory model
-
Result:Exacerbated inflammation and increased eosinophils in the acute model.
Did not affect inflammation or cytokine production in the memory model.
-
Animal Model:9×105 Tregs-IL2pa male B6 Thy1.2 mice (12-20 weeks)[2]
-
Dosage:250 μg
-
Administration:Intraperitoneal injection (i.p.), single dose, 133 days after the injection of Tregs-IL2pa
-
Result:Could effectively clear Tregs-IL2pa marked with Thy1.1 and the removal effect was long-lasting.
-
Animal Model:MOG35-55 (200 μg) induced C57BL/6 mice[3]
-
Dosage:200 µg
-
Administration:Intraperitoneal injection (i.p.), once every other day, until symptoms of the disease appear
-
Result:Significantly inhibited the development of EAE.
Significantly reduced EAE score.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo T cell depletion
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse Thy1.1/CD90.1 Antibody (19E12)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Yadava K, et al. Natural Tr1-like cells do not confer long-term tolerogenic memory. Elife. 2019 Oct 11;8:e44821. [Content Brief]
[2]. Robert J, et al. Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models. Nat Commun. 2025 May 27;16(1):4891. [Content Brief]
[3]. Heink S, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2017 Jan;18(1):74-85. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz